keyword
MENU ▼
Read by QxMD icon Read
search

Neuroendocrine pancreatic tumor

keyword
https://www.readbyqxmd.com/read/29782352/an-update-on-the-management-of-pancreatic-neuroendocrine-tumors
#1
Limin Gao, Nikola S Natov, Kevin P Daly, Faisal Masud, Sadia Chaudhry, Mark J Sterling, Muhammad W Saif
Pancreatic neuroendocrine tumors (PNETs) are a rare and heterogeneous group of neoplasia and differ in their clinical presentation, behavior, and prognosis based on both histological features and cancer stage at the time of diagnosis. Although small-sized tumors can be surgically resected, locally advanced and metastatic tumors confer a poor prognosis. In addition, only limited treatment options are available to the latter group of patients with PNETs, such as hormonal analogs, cytotoxic agents, and targeted therapy...
May 8, 2018: Anti-cancer Drugs
https://www.readbyqxmd.com/read/29781720/supplementation-of-vitamin-d-deficiency-in-patients-with-neuroendocrine-tumors-using-over-the-counter-vitamin-d3-preparations
#2
Helen L Robbins, Megan Symington, Barbara Mosterman, Josie Goodby, Louise Davies, Georgios K Dimitriadis, Gregory Kaltsas, Harpal S Randeva, Martin O Weickert
Vitamin D (vit-D) deficiency is highly prevalent in patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) and has been linked to reduced overall survival. We here assessed the vit-D status in 183 patients with GEP-NET at the time of their first presentation in the ARDEN NET Centre. We further examined the effect of simple advice to increase vit-D intake using over-the-counter vit-D preparations [colecalciferol (Vit-D3), 1,000-2,000 units/day], over a prospective observation period of 24 mo...
May 21, 2018: Nutrition and Cancer
https://www.readbyqxmd.com/read/29765522/establishment-of-preclinical-chemotherapy-models-for-gastroenteropancreatic-neuroendocrine-carcinoma
#3
Akihiro Ohmoto, Masami Suzuki, Erina Takai, Hirofumi Rokutan, Yuko Fujiwara, Chigusa Morizane, Kazuyoshi Yanagihara, Tatsuhiro Shibata, Shinichi Yachida
Gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) is a rare and devastating malignancy, and preclinical studies are needed to evaluate potential therapeutic regimens. Here, we examined the antitumor effects of cisplatin (CDDP), etoposide (ETP) and irinotecan (CPT-11) and their combinations on GEP-NEC using three small-cell GEP-NEC cell lines (pancreatic NEC, A99; esophageal NEC, TYUC-1; duodenum NEC, TCC-NECT-2). In vitro studies were conducted using cell viability assays. In vivo experiments were conducted in mice inoculated with A99 or TCC-NECT-2 and treated with no agent, CDDP, CDDP+ETP (EP) or CDDP+CPT-11 (IP)...
April 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29763717/hepatic-micrometastases-are-associated-with-poor-prognosis-in-patients-with-liver-metastases-from-neuroendocrine-tumors-of-the-digestive-tract
#4
William E Gibson, Raul S Gonzalez, Justin M M Cates, Eric Liu, Chanjuan Shi
Pathologic examination of hepatic metastasectomies from patients with metastatic small intestinal or pancreatic neuroendocrine tumor frequently reveals micrometastases undetectable by radiologic or macroscopic gross examination. This finding raises the possibility that undetectable micrometastases remain in these patients after metastasectomy. Here we examined liver resections for micrometastases and assessed their impact on prognosis. Hepatic metastasectomies from 65 patients with neuroendocrine tumor of the small intestine (N=43) or pancreas (N=22) were reviewed for the presence of micrometastases, which were defined as microscopic tumor foci ≤1mm in greatest dimension...
May 12, 2018: Human Pathology
https://www.readbyqxmd.com/read/29762236/acute-pancreatitis-following-peptide-receptor-radionuclide-therapy-an-unusual-adverse-event
#5
Ioannis Karfis, Gwennaëlle Marin, Godelieve Machiels, Alain Hendlisz, Patrick Flamen
A 54-year-old man with grade 2 rectal neuroendocrine tumor and hepatic, pancreatic, and bone metastases was treated with Lu-DOTATATE as second-line therapy, after failure of somatostatin analogues. Two weeks after the first injection, he presented at the emergency department with acute pancreatitis. We hypothesized that this unusual adverse event, never been reported so far, was the result of acute tumor irradiation after PRRT, leading to peritumoral inflammation and edema with obstruction of an accessory pancreatic duct...
May 14, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29760809/the-latest-exploration-of-staging-and-prognostic-classification-for-pancreatic-neuroendocrine-tumors-a-large-population-based-study
#6
Shanshan Gao, Ning Pu, Lingxiao Liu, Changyu Li, Xuefeng Xu, Xiaolin Wang, Wenhui Lou
Background: A modified European Neuroendocrine Tumor Society (mENETS) staging system has been confirmed to be more suitable for pancreatic neuroendocrine tumors (pNETs) when compared to the American Joint Committee on Cancer (AJCC) or the European Neuroendocrine Tumor Society (ENETS) systems in the last few years. However, the importance of N stage has been recently published with several significant updates. Methods: SEER registry (n = 2,209) was used to evaluate the application of the AJCC 7th staging system, ENETS staging system, mENETS staging system and reformed ENETS (rENETS) staging system in this study...
2018: Journal of Cancer
https://www.readbyqxmd.com/read/29760558/pretreatment-hematologic-markers-as-prognostic-predictors-of-gastroenteropancreatic-neuroendocrine-tumors-a-systematic-review-and-meta-analysis
#7
Yu Zhou, Dezhi Li, Ye Lin, Min Yu, Xin Lu, Zhixiang Jian, Ning Na, Baohua Hou
Background: Systemic inflammation can be reflected by peripheral hematologic parameters and combined index like the lymphocyte count, neutrophil count, platelet count, neutrophil-to-lymphocyte (NLR), and platelet-to-lymphocyte ratio (PLR). This systematic review and meta-analysis aimed to summarize the association between the hematologic markers and prognosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Methods: A computerized systematic search of PubMed, Embase, and Web of Science was conducted up to August 2016...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29755017/endoscopic-papillectomy-of-benign-ampullary-lesions-outcomes-from-a-multicenter-study
#8
Tan Attila, Erkan Parlak, Emrah Alper, Selçuk Dişibeyaz, Bahattin Çiçek, Bülent Ödemiş
BACKGROUND/AIMS: Endoscopic papillectomy (EP) has emerged as an alternative to surgery in the management of ampullary lesions. The aim of this study is to evaluate feasibility, efficacy, safety, outcome, and impact of EP in the management of benign ampullary lesions. MATERIALS AND METHODS: This is a multicenter, retrospective study of 44 patients who had EP of benign ampullary lesions. RESULTS: Over the 11-year period, 44 (55.7%) of 79 patients underwent EP for benign ampullary lesions...
May 2018: Turkish Journal of Gastroenterology: the Official Journal of Turkish Society of Gastroenterology
https://www.readbyqxmd.com/read/29748738/distal-pancreatectomy-combined-with-multivisceral-resection-is-associated-with-postoperative-complication-rates-and-survival-comparable-to-those-after-standard-procedures
#9
Thomas Malinka, Fritz Klein, Andreas Andreou, Johann Pratschke, Marcus Bahra
BACKGROUND: For pancreatic tumors located in the body or tail of the pancreas, distal pancreatectomy (DP) remains the surgical procedure of choice to achieve radical tumor removal. Purpose of this study was to evaluate outcome and overall survival of patients who underwent DP combined with multivisceral resection (MVR). METHODS: Retrospective single-center case-matched analysis. Between January 1994 and June 2014, 494 consecutive patients were entered into a prospective database, and 126 patients undergoing DP + MVR (cases) were matched with 126 patients undergoing DP (controls) for gender, age, and underlying final diagnosis...
May 10, 2018: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/29748190/preventive-medicine-for-von-hippel-lindau-disease-associated-pancreatic-neuroendocrine-tumors
#10
Tobias Krauss, Alfonso Massimiliano Ferrara, Thera P Links, Ulrich Wellner, Irina Bancos, Andrey Kvachenyuk, Karina Villar Gómez de Las Heras, Marina Yukina, Roman Petrov, Garrett Bullivant, Laura von Duecker, Swati S Jadhav, Ursula Ploeckinger, Staffan Welin, Camilla Schalin-Jantti, Oliver Gimm, Marija Pfeifer, Joanne Ngeow, Kornelia Hasse-Lazar, Gabriela Sanso, Xiao-Ping Qi, Umit Ugurlu, Rene Eduardo Diaz, Nelson Wohllk, Mariola Peczkowska, Jens Aberle, Delmar Munir Lourenço, Maria Adelaide Pereira, Maria Candida Barisson Villares Fragoso, Ana O Hoff, Madson Queiroz Almeida, Alice H D Violante, Ana R P Quidute, Zheiwei Zhang, Monica Recasens, Luis Robles Diaz, Tada Kunavisarut, Taweesak Wannachalee, Sirinart Sirinvaravong, Eric Jonasch, Simona Grozinsky-Glasberg, Merav Fraenkel, Dmitry Beltsevich, Viacheslav I Egorov, Dirk Bausch, Matthias Schott, Nikolaus Tiling, Gianmaria Pennelli, Stefan Zschiedrich, Roland Därr, Juri Ruf, Timm Denecke, Karl-Heinrich Link, Stefania Zovato, Ernst von Dobschuetz, Svetlana Yaremchuk, Holger Amthauer, Ozer Makay, Attila Patocs, Martin K Walz, Tobias B Huber, Jochen Seufert, Per Hellman, Raymond H Kim, Ekaterina Kuchinskaya, Francesca Schiavi, Angelica Malinoc, Nicole Reisch, Barbara Jarzab, Marta Barontini, Andrzej Januszewicz, Nalini Shah, William Young, Giuseppe Opocher, Charis Eng, Hartmut P H Neumann, Birke Bausch
Pancreatic neuroendocrine tumors (PanNETs) are rare in von Hippel-Lindau disease (VHL) but cause serious morbidity and mortality. Management guidelines for VHL-PanNETs continue to be based on limited evidence, and survival data to guide surgical management are lacking. We established the European-American-Asian-VHL-PanNET-Registry to assess data for risks for metastases, survival and long-term outcomes to provide best management recommendations. Of 2,330 VHL patients, 273 had a total of 484 PanNETs. Median age at diagnosis of PanNET was 35 years (range 10-75)...
May 10, 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29744856/risk-factors-associated-with-gastroenteropancreatic-neuroendocrine-tumors-gep-net-in-a-cohort-of-2-3-million-israeli-adolescents
#11
L H Katz, Z Levi, G Twig, J D Kark, A Leiba, E Derazne, I Liphshiz, L K Boker, S Eisenstein, A Afek
We investigated whether obesity and socio-demographic factors at adolescence are associated with incident gastroenteropancreatic neuroendocrine tumors (GEP-NET).Our cohort included 2.3 million Israeli adolescents examined at ages 16 to 19 years between 1967 and 2010. The baseline database included sex, country of birth, residential socio-economic status (SES), body-mass index (BMI) and height. Participants were followed through linkage with the National Cancer Registry up to 2012. We identified 221 cases of GEP-NET (66 pancreatic, 52 gastric, 39 rectal, 27 appendiceal, 23 small bowel and 14 colonic)...
May 9, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29742602/impressive-response-to-tandem-treatment-with-90y-dotatoc-and-177lu-dotatoc-in-grade-3-pancreatic-neuroendocrine-carcinoma
#12
Alice Lorenzoni, Antonella Capozza, Salvatore Artale, Marco Maccauro, Ettore Cesare Seregni
Peptide receptor radionuclide therapy is an effective, well-tolerated, treatment for well-differentiated neuroendocrine tumors, resulting in a significant survival benefit and improvement of quality of life. Very few data are available on peptide receptor radionuclide therapy effectiveness in grade 3 neuroendocrine carcinomas with high somatostatin receptor expression. We report the case of a 70-year-old woman with metastatic pancreatic grade 3 neuroendocrine carcinoma who underwent 6 cycles of tandem treatment with investigational radiopharmaceuticals Y-DOTATOC and Lu-DOTATOC achieving an impressive response...
May 7, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29739948/a-meta-analysis-of-prognostic-factor-of-pancreatic-neuroendocrine-neoplasms
#13
Yong Gao, Hao Gao, Guangfu Wang, Lingdi Yin, Wenbin Xu, Yunpeng Peng, Junli Wu, Kuirong Jiang, Yi Miao
Pancreatic neuroendocrine neoplasms (pNENs) are a group of clinically rare and heterogeneous diseases of the pancreas. However, the prognostic factors for this disease in patients still remain controversial. The purpose of our study is to evaluate the predictive roles of those prognostic factors for pNENs. All related articles published until Sep 17, 2017 were identified via PubMed, EMBASE, Web of Science, Ovid and the Cochrane Library. Studies that examined the prognostic factors of pNENs were enrolled. 17 articles (2822 patients) were finally included in this study...
May 8, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29739787/curation-of-the-pancreatic-ductal-adenocarcinoma-subset-of-the-cancer-genome-atlas-is-essential-for-accurate-conclusions-about-survival-related-molecular-mechanisms
#14
Ivana Peran, Subha Madhavan, Stephen W Byers, Matthew D McCoy
PURPOSE:  Publically available databases, e.g. The Cancer Genome Atlas (TCGA), containing clinical and molecular data from large number of patients are useful in validating the contribution of particular genes to disease mechanisms and in forming novel hypotheses relating to clinical outcomes. EXPERIMENTAL DESIGN:  The impact of key drivers of cancer progression can be assessed by segregating a patient cohort by certain molecular features and constructing survival plots using the associated clinical data...
May 8, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29731245/the-prognostic-impact-of-primary-tumor-resection-in-pancreatic-neuroendocrine-tumors-with-synchronous-multifocal-liver-metastases
#15
Chen Lin, Hongmei Dai, Xiafei Hong, Haiyu Pang, Xianze Wang, Peiran Xu, Jialin Jiang, Wenming Wu, Yupei Zhao
BACKGROUND: Whether primary tumor resection benefits patients with synchronous multifocal liver metastases from pancreatic neuroendocrine tumors remains controversial. We investigated whether primary tumor resection significantly affects survival in this study. METHODS: A retrospective study of patients with synchronous multifocal liver metastases from pancreatic neuroendocrine tumors between 1998 and 2016 was performed. Patient demographics, operation details, adjuvant treatment, and pathological and survival information were collected, and relevant clinical-pathological parameters were assessed in univariate and multivariate survival analyses...
April 30, 2018: Pancreatology: Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]
https://www.readbyqxmd.com/read/29727904/endoscopic-ultrasound-guided-radiofrequency-ablation-for-management-of-benign-solid-pancreatic-tumors
#16
Jun-Ho Choi, Dong-Wan Seo, Tae Jun Song, Do Hyun Park, Sang Soo Lee, Sung Koo Lee, Myung-Hwan Kim
BACKGROUND:  Radiofrequency ablation (RFA) has been increasingly employed in experimental and clinical settings for the management of pancreatic lesions. This study aimed to assess the safety and efficacy of endoscopic ultrasound (EUS)-guided RFA for benign solid pancreatic tumors. METHODS:  In a single-center, prospective study, 10 patients with benign solid pancreatic tumors underwent EUS-RFA. After the RFA electrode had been inserted into the pancreatic mass, the radiofrequency generator was activated to deliver 50 W of ablation power...
May 4, 2018: Endoscopy
https://www.readbyqxmd.com/read/29725435/uncovering-the-heterogeneous-genetic-variations-in-two-insulin-expressing-tumors-in-a-patient-with-men1
#17
Zai Wang, Liguo Liu, Jie Luo, Jing Guo, Min Zhai, Wenjian Zhang, Zhiying Yang
Multiple endocrine neoplasia type 1 (MEN1) is associated with a heterozygous inherited mutation of the menin 1 ( MEN1 ) gene; however, the molecular pathogenesis remains to be fully elucidated. In the present study, whole exome sequencing was performed on two pancreatic neuroendocrine tumors (PNETs), termed T1 and T2, peri-tumoral tissue (PT) and a blood sample obtained from a patient with MEN1. The cells in T1 and T2, but not PT, showed loss of chromosome 11 where MEN1 was located, confirming that the loss of heterozygosity (LOH) of MEN1 was a crucial event in tumorigenesis...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29723285/vasostatin-1-a-novel-circulating-biomarker-for-ileal-and-pancreatic-neuroendocrine-neoplasms
#18
Andrea Corsello, Luigi Di Filippo, Sara Massironi, Federica Sileo, Anna Dolcetta Capuzzo, Marco Gemma, Claudia Carlucci, Claudio Cusini, Barbara Colombo, Alice Dallatomasina, Giulia Maria Franchi, Angelo Corti, Marco Federico Manzoni
BACKGROUND: Chromogranin A (CgA) is a plasma biomarker widely used in the follow-up of patients with neuroendocrine neoplasms (NENs). However, its accuracy as a tumor biomarker is relatively low because plasma CgA can increase also in patients with other diseases or in subjects treated with proton-pump inhibitors (PPIs), a class of widely-used drugs. METHODS: In the attempt to identify a more reliable biomarker for NENs, we investigated, by ELISA, the circulating levels of full-length CgA (CgA1-439) and of various CgA-derived fragments in 17 patients with ileal or pancreatic NENs, 10 healthy controls, and 21 healthy volunteers before and after treatment with PPIs...
2018: PloS One
https://www.readbyqxmd.com/read/29721608/c-myc-amplification-and-c-myc-protein-expression-in-pancreatic-acinar-cell-carcinomas-new-insights-into-the-molecular-signature-of-these-rare-cancers
#19
Stefano La Rosa, Barbara Bernasconi, Alessandro Vanoli, Amedeo Sciarra, Kenji Notohara, Luca Albarello, Selenia Casnedi, Paola Billo, Lizhi Zhang, Maria Grazia Tibiletti, Fausto Sessa
The molecular alterations of pancreatic acinar cell carcinomas (ACCs) and mixed acinar-neuroendocrine carcinomas (MANECs) are not completely understood, and the possible role of c-MYC amplification in tumor development, progression, and prognosis is not known. We have investigated c-MYC gene amplification in a series of 35 ACCs and 4 MANECs to evaluate its frequency and a possible prognostic role. Gene amplification was investigated using interphasic fluorescence in situ hybridization analysis simultaneously hybridizing c-MYC and the centromere of chromosome 8 probes...
May 2, 2018: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/29713473/nkx2-2-pdx-1-and-cdx-2-as-potential-biomarkers-to-differentiate-well-differentiated-neuroendocrine-tumors
#20
Michelle X Yang, Ryan F Coates, Abiy Ambaye, Valerie Cortright, Jeannette M Mitchell, Alexa M Buskey, Richard Zubarik, James G Liu, Steven Ades, Maura M Barry
Background: Well-differentiated neuroendocrine tumors (NET) most frequently arise from the gastrointestinal tract (GI), pancreas, and lung. Patients often present as metastasis with an unknown primary, and the clinical management and outcome depend on multiple factors, including the accurate diagnosis with the tumor primary site. Determining the site of the NET with unknown primary remains challenging. Many biomarkers have been investigated in primary NETs and metastatic NETs, with heterogeneous sensitivity and specificity observed...
2018: Biomarker Research
keyword
keyword
27835
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"